Canine immuno-oncology
Ended Awarded Last action
- Contract number
- HHSN26100053
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,408,319
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $18,408,319.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $18,408,319 |
About this award
This is a federal contract award from the Department of Health and Human Services' National Institutes of Health (NIH) National Cancer Institute to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $18,408,319.00 contract is for work related to "CANINE IMMUNO-ONCOLOGY" and is a Delivery Order with a Cost Plus Fixed Fee pricing type. The contract does not have a set-aside designation and was awarded on September 21, 2017, with a completion date of September 20, 2022.
Leidos Biomedical Research is a Federally Funded Research and Development Center (FFRDC) for the National Cancer Institute, providing a broad range of biomedical research and facilities support services. Through past work, Leidos Biomedical Research has supported various NIH research initiatives, including in areas like cancer, HIV/AIDS, influenza, COVID-19, and gene therapy. The parent company, Leidos, has also served as a subcontractor on other federal contracts, providing services, engineering support, and programmatic support.
Quick answers
Who was awarded contract HHSN26100053?
HHSN26100053 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 21, 2017.
How much is contract HHSN26100053 worth?
The government has obligated $18,408,319 on HHSN26100053.
Is contract HHSN26100053 an order under another contract?
Yes. HHSN26100053 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100053 competed?
The extent of competition for HHSN26100053 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award